Albumin dialysis: Current practice and future options

Liver International

Volumn 31, Issue SUPPL. 3, 2011, Pages 9-12

  Wauters, Joost ^a   Wilmer, Alexander ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Albumin dialysis; Liver failure

Indexed keywords

ALBUMIN; ANION EXCHANGE RESIN; BILIRUBIN; CHARCOAL; CITRIC ACID; CREATININE; HEPARIN; PARACETAMOL; TOXIN;

ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ADSORPTION; ALBUMIN DIALYSIS; ALUMINUM DIALYSATE LEVEL; ANTICOAGULANT THERAPY; BILIRUBIN BLOOD LEVEL; BLEEDING; BRAIN EDEMA; CHEMICAL ANALYSIS; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HUMAN; INTRACRANIAL HYPERTENSION; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER SUPPORT; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SYMPTOM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

HEMODYNAMICS; HUMANS; LIVER FAILURE; RENAL DIALYSIS; SERUM ALBUMIN; SORPTION DETOXIFICATION;

EID: 79961191557     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02589.x     Document Type: Review

References (11)

1. Laleman W, Wilmer A, Evenepoel P, et al. Review article: non-biological liver support in liver failure. Aliment Pharmacol Ther 2006; 23: 351-63.
2. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-13.
3. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
4. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-58.
5. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.
6. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109-19.
7. Kantola T, Ilmakunnas M, Koivusalo AM, Isoniemi H. Bridging therapies and liver transplantation in acute liver failure, 10 years of MARS experience from Finland. Scand J Surg 2011; 100: 8-13.
8. Saliba F, Camus C, Durand F, et al. Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology 2008; 48 (Suppl.): 377A.
9. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.
10. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010; 59: 381-6.
11. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver 2003; 9: 290-7.